Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study

• Main Authors: Yoshimi Muta (Author), Kazuo Kobayashi (Author), Masao Toyoda (Author), Atsuhito Tone (Author), Daisuke Suzuki (Author), Daisuke Tsuriya (Author), Hideo Machimura (Author), Hidetoshi Shimura (Author), Hiroshi Takeda (Author), Hisashi Yokomizo (Author), Kei Takeshita (Author), Keiichi Chin (Author), Keizo Kanasaki (Author), Kouichi Tamura (Author), Masaaki Miyauchi (Author), Masuo Saburi (Author), Miwa Morita (Author), Miwako Yomota (Author), Moritsugu Kimura (Author), Nobuo Hatori (Author), Shinichi Nakajima (Author), Shun Ito (Author), Shunichiro Tsukamoto (Author), Takashi Murata (Author), Takaya Matsushita (Author), Takayuki Furuki (Author), Takuya Hashimoto (Author), Tomoya Umezono (Author), Yuichi Takashi (Author), Daiji Kawanami (Author)
• Format: Book
• Published: Frontiers Media S.A., 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Accumulating evidence has demonstrated that both SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP1Ra) have protective effects in patients with diabetic kidney disease. Combination therapy with SGLT2i and GLP1Ra is commonly used in patients with type 2 diabetes (T2D). We previously reported...